Sentence-ID,Sentence-String,Q1,Q2,Q3,Q4,Q5,Q6,Q7,Q8,Q9,Q10,Q11
0,"The omega-3 index represents the red blood cell (RBC) content of two major long-chain n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).",0,0,0,0,0,0,0,0,0,0,0
1,We sought to determine factors associated with a favorable response to fish oil treatment as well as to characterize changes in RBC PUFAs associated with fish oil supplementation.,0,0,0,0,0,0,0,0,0,0,0
2,"This study was a secondary analysis of the OMEGA-PAD I Trial, a randomized, double-blinded, placebo-controlled trial investigating short-duration, high-dose n-3 PUFA oral supplementation on endothelial function and inflammation in subjects with peripheral arterial disease (PAD).",0,0,0,0,0,0,1,0,0,0,0
3,Patients with mild to severe claudication received either 4.4g of fish oil providing 2.6g of EPA + 1.8g of DHA daily (n=40) or placebo capsules (n=40) for 1 month.,0,0,0,0,0,0,1,0,0,0,0
4,The RBC fatty acid content was measured by gas chromatography and expressed as a percent of total fatty acids.,1,0,0,0,0,1,1,0,0,0,0
5,The change in omega-3 index was calculated as the difference between pre- and post-supplementation in the fish oil and placebo groups.,0,0,0,0,0,0,1,0,0,0,0
6,"Univariate analysis identified predictors of change in omega-3 index, with these variables included in our multivariable model.",0,0,0,0,0,0,1,0,0,0,0
7,"In the fish oil group, there was an increase in the omega-3 index (5.1 ± 1.3% to 9.0 ± 1.8%; p&lt;0.0001), whereas there was no change in the control group.",0,0,0,1,0,0,0,1,1,1,1
8,"Factors associated with a favorable response (i.e., greater than the median change of 4.06%) included a lower body mass index (BMI) and higher concentrations of low-density lipoproteins (LDL).",0,0,0,1,0,0,0,1,1,1,1
9,"Other demographic/lifestyle factors such as age, race, or smoking status were unrelated to the response.",0,0,0,1,0,0,0,1,1,1,1
10,Oral n-3 PUFA supplementation also decreased the n-6 PUFA content in RBCs.,1,0,0,1,0,1,0,1,1,1,1
11,"Short-term, high-dose n-3 PUFA supplementation increases the omega-3 index to a greater extent in patients with a lower BMI and higher total and LDL cholesterol levels.",0,0,0,0,0,0,0,0,0,0,0
12,"Peripheral arterial disease (PAD), a chronic inflammatory condition affecting the vasculature, continues to be associated with a high risk of cardiovascular events and mortality compared to coronary artery disease (CAD), despite the wide availability of medical and interventional therapies (<sup><a href=""#R1"">1</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
13,"Current nutritional guidelines from the American Heart Association and American College of Cardiology recommend a diet rich in oily fish for individuals with cardiovascular disease, including peripheral arterial disease (PAD) (<sup><a href=""#R2"">2</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
14,"Evidence demonstrates that n-3 PUFA play a role in reducing systemic inflammation (<sup><a href=""#R3"">3</a></sup>) and protecting against the development of atherosclerosis (<sup><a href=""#R4"">4</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
15,"A widely used biomarker of n-3 PUFA status is the omega-3 index, which represents the level of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell (RBC) membranes (<sup><a href=""#R5"">5</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
16,"This marker is a well-documented surrogate of the EPA+DHA status of other tissues (<sup><a href=""#R6"">6</a></sup><sup>–</sup><sup><a href=""#R8"">8</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
17,"The omega-3 index is inversely associated with a high-risk CAD profile (<sup><a href=""#R9"">9</a></sup>) and inflammatory markers (<sup><a href=""#R10"">10</a></sup>), and has been proposed as an actual risk factor for death from CAD (<sup><a href=""#R5"">5</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
18,"Therefore, a relatively low membrane concentration of <span class=""italic"">n</span>-3 PUFA may contribute to the development and progression of PAD (<sup><a href=""#R11"">11</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
19,"We have previously reported that in patients with PAD, a higher omega-3 index was associated with older age, elevated body mass index (BMI), and prior fish oil supplementation, while a history of smoking correlated with a lower omega-3 index (<sup><a href=""#R12"">12</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
20,"We also demonstrated the ability of high-dose, short duration n-3 PUFA supplementation to increase the omega-3 index in patients with PAD (<sup><a href=""#R13"">13</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
21,Determining those factors involved in a robust response to n-3 PUFA supplementation could help guide treatment considerations in patients with PAD.,0,0,0,0,0,0,0,0,0,0,0
22,"The goal of this analysis was, therefore, to identify factors associated with a favorable response to fish oil treatment.",0,0,0,0,0,0,0,0,0,0,0
23,We also aimed to characterize changes in other RBC fatty acids with n-3 PUFA supplementation.,1,0,0,0,0,1,0,0,0,0,0
24,"The methods of the OMEGA-PAD I (NCT01310270) Trial, a randomized, double-blinded, placebo-controlled trial designed to assess the impact of high-dose, short-term <span class=""italic"">n</span>-3 PUFA supplementation on endothelial function and inflammation in patients with symptomatic PAD, have been previously published (<sup><a href=""#R14"">14</a></sup>).",0,1,1,0,1,0,0,0,0,0,0
25,"The current study is a secondary analysis utilizing data from that trial to investigate baseline omega-3 indices in PAD patients, absolute change in the omega-3 index after a one-month course of high-dose <span class=""italic"">n</span>-3 PUFA supplementation, and predictors of omega-3 index response.",0,0,1,0,1,0,0,0,0,0,0
26,"Eighty patients with stable, mild or severe claudication (Rutherford Class 1 to 3) received either 4.4g of fish oil capsules consisting of 2.6g of EPA and 1.8g of DHA daily (n=40) or placebo capsules (n=40) for 1 month.",0,0,1,0,1,0,0,0,0,0,0
27,"The placebo capsules were the same shape and color as the fish oil capsules, and the same quantity of capsules was taken daily by all participants in both cohorts.",0,0,1,0,1,0,0,0,0,0,0
28,"The omega-3 index was analyzed according to the HS-Omega-3 index® methodology (<sup><a href=""#R15"">15</a></sup>).",0,0,1,0,1,0,0,0,0,0,0
29,Baseline clinical and demographic characteristics of the intervention and placebo groups were compared using chi-square tests for categorical variables and unpaired t-tests for continuous variables.,0,0,0,0,0,0,0,0,0,0,0
30,Changes in RBC PUFA composition from pre- to post-intervention were compared within and between intervention groups using paired t-tests for within-group comparisons and unpaired t-tests for between group comparisons.,0,0,0,0,0,0,0,0,0,0,0
31,"Within only the intervention group, factors associated with a change in omega-3 were examined for two levels of response: 1) a difference greater than the median response, and 2) a difference greater than the 75<sup>th</sup> percentile response.",0,0,0,0,0,0,0,0,0,0,0
32,We first used univariate logistic regression models to examine each characteristic for potential association with change in level of omega-3 index.,0,0,0,0,0,0,0,0,0,0,0
33,We then constructed multivariable logistic regression models including predictors that were significant at the 0.05 level in univariate analysis and adjusted for age.,0,0,0,0,0,0,0,0,0,0,0
34,The models were restricted to those subjects who were in the intervention group (n=40).,0,0,0,0,0,0,0,0,0,0,0
35,"When predictors were highly correlated with one another, we chose to include the predictor which yielded the highest c-statistic contributed the most information.",0,0,0,0,0,0,0,0,0,0,0
36,An alpha-level of 0.05 was used to determine significance.,0,0,0,0,0,0,0,0,0,0,0
37,"All statistical analyses were performed using Stata/SE 13 (StataCorp, College Station, TX).",0,0,0,0,0,0,0,0,0,0,0
38,"The baseline characteristics and clinical profiles of the two intervention groups have been previously published (<sup><a href=""#R13"">13</a></sup>) and are included in <a href=""#T1"">Table 1</a>.",0,0,0,1,0,0,0,1,1,1,1
39,"The two groups were similar at baseline as all subjects were primarily male, Caucasian, and in their mid-sixties.",0,0,0,0,0,0,0,0,0,0,0
40,"The majority of their cardiovascular and PAD risk factors were also similar, with a history of CAD being the only exception.",0,0,0,0,0,0,0,0,0,0,0
41,The fish oil cohort had 33% of patients with known CAD compared to 55% of patients in the placebo cohort (p=0.04).,0,0,0,0,0,0,0,0,0,0,0
42,"The baseline omega-3 index (<a href=""#F1"">Figure 1</a>) averaged 5%, with a right-tail skew seen in both cohorts.",0,0,0,0,0,0,0,0,0,0,0
43,"Following one month of fish oil supplementation, the mean increase in the omega-3 index was 3.99 ± 1.4% (p&lt;0.0001) in the supplemented fish oil group, while no change was seen in the control group (+0.11 ± 0.91, p=0.49) (<a href=""#F2"">Figure 2</a>).",0,0,0,0,0,0,0,0,0,0,0
44,"The increase in the n-3 PUFAs was accompanied by a decrease in the n-6 PUFAs, as well as cis-monosaturated fatty acids and trans fatty acids (<a href=""#T2"">Table 2</a>).",0,0,0,0,0,0,0,0,0,0,0
45,"Table 3</a> identifies factors associated with a more (vs. less) robust response comparing those whose omega-3 index increased by more than the median response across all subjects (i.e., &gt;4.06%) to those whose increase was less than the median.",0,0,0,0,0,0,0,0,0,0,0
46,"<a href=""#T3"">Table 3</a> also identifies factors associated with a more robust response comparing those whose omega-3 index increased by more than the 75<sup>th</sup> percentile to those whose increase fell below this level.",0,0,0,0,0,0,0,0,0,0,0
47,"Baseline levels of total and low-density lipoprotein (LDL) cholesterol were directly associated with a more robust response, while BMI was inversely associated with such a response.",0,0,0,0,0,0,0,0,0,0,0
48,"For every 10 mg/dL higher the level of total and LDL cholesterol, the likelihood of an above-median change in omega-3 index increased by 25%, while for every one-unit greater the BMI, the likelihood of an abovemedian change in omega-3 index decreased by almost 20%.",0,0,0,0,0,0,0,0,0,0,0
49,"In multivariable analysis, LDL cholesterol (OR 1.28, 95% CI 1.02 to 1.60) remained independently associated with an increased likelihood of an above-median change in the omega-3 index, and BMI (OR 0.78, 95% CI 0.62 to 0.97) maintained an inverse relationship to an above-median response (<a href=""#T4"">Table 4</a>).",0,0,0,0,0,0,0,0,0,0,0
50,"A Hosmer-Lemeshow goodness of fit test indicated a good fit for the model (p=0.35), which yielded a c-statistic (area under the ROC curve) of 0.83.",0,0,0,0,0,0,0,0,0,0,0
51,"Although age was not significant in univariate analysis, we adjusted for age in the multivariable model.",0,0,0,0,0,0,0,0,0,0,0
52,"Furthermore, omitting age also resulted in a slightly lower c-statistic (0.82).",0,0,0,0,0,0,0,0,0,0,0
53,"In this study, compliance (defined by pill count) was not significantly associated with omega-3 index response.",0,0,0,0,0,0,0,0,0,0,0
54,"A one month-long, high-dose fish oil intervention was found to increase the omega-3 index, increasing the total omega-3 fatty acids and decreasing the n-6 PUFA in the RBC membrane.",0,0,0,0,0,0,0,0,0,0,0
55,A stronger response to n-3 PUFA was seen in those patients with lower BMI as well as those with higher LDL and total cholesterol.,0,0,0,0,0,0,0,0,0,0,0
56,"PAD is associated with heightened systemic vascular inflammation (<sup><a href=""#R16"">16</a></sup>) and elevated risk of cardiovascular events and mortality (<sup><a href=""#R1"">1</a></sup><sup>, </sup><sup><a href=""#R17"">17</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
57,"Endothelial dysfunction is believed to be an important contributing mechanism to the progression of atherosclerosis (<sup><a href=""#R18"">18</a></sup><sup>–</sup><sup><a href=""#R20"">20</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
58,"n-3 PUFA supplementation has long been recognized to have beneficial effects on cardiovascular health, with current evidence suggesting that n-3 PUFA may improve both systemic inflammation and vascular function in patients with PAD (<sup><a href=""#R13"">13</a></sup><sup>, </sup><sup><a href=""#R21"">21</a></sup><sup>–</sup><sup><a href=""#R23"">23</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
59,"The omega-3 index is a validated biomarker of <span class=""italic"">n</span>-3 PUFA status based on data demonstrating that the EPA + DHA content in RBC membranes provides an accurate estimate of overall <span class=""italic"">n</span>-3 PUFA intake (<sup><a href=""#R24"">24</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
60,"n-3 PUFAs derived from fish oil have been found to yield beneficial effects on cardiovascular health (<sup><a href=""#R25"">25</a></sup><sup>, </sup><sup><a href=""#R26"">26</a></sup>), including decreasing mortality from cardiovascular causes, all-cause mortality, and non-fatal cardiovascular events (<sup><a href=""#R27"">27</a></sup><sup>–</sup><sup><a href=""#R30"">30</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
61,"Our previous work has shown that predictors of higher omega-3 index in patients with PAD were older age, elevated BMI and prior fish oil supplementation (<sup><a href=""#R12"">12</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
62,Here we investigated the predictors of a response to fish oil supplementation and found that a lower BMI and higher LDL cholesterol were the only independent predictors of a favorable response in the omega-3 index.,0,0,0,0,0,0,0,0,0,0,0
63,"With respect to the effect seen in subjects with higher LDL levels, we believe this could be partially explained by increased circulating phosphotidylserine (PL)-esterified fatty acid levels.",0,0,0,0,0,0,0,0,0,0,0
64,"With fish oil supplementation, EPA and DHA are first incorporated into plasma lipids, especially PL (<sup><a href=""#R31"">31</a></sup>), a large part of which are found in LDL.",0,0,0,0,0,0,0,0,0,0,0
65,"Subsequently, RBC membrane PLs may exchange with plasma PL (<sup><a href=""#R32"">32</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
66,"Therefore, increased response of RBC n-3 PUFA with fish oil supplementation may be secondary to the presence of increased circulating LDL, which are the reservoir of EPA and DHA prior to membrane incorporation.",0,0,0,0,0,0,0,0,0,0,0
67,The better response in omega-3 index seen in those individuals with a lower BMI could be explained by the fact that the dose per kg body weight is higher in individuals with lower body weights.,0,0,0,0,0,0,0,0,0,0,0
68,"Therefore, clinical consideration could be given to providing a weight-based dosing schedule related to the patient’s BMI.",0,0,0,0,0,0,0,0,0,0,0
69,The factors identified in this study as predictors of a robust response to n-3 PUFA supplementation could help guide treatment considerations in patients with PAD.,0,0,0,0,0,0,0,0,0,0,0
70,"Guidelines from the American Heart Association recommend that individuals with cardiovascular disease incorporate fish into their diets and supplement daily with n-3 PUFA (<sup><a href=""#R33"">33</a></sup><sup>–</sup><sup><a href=""#R35"">35</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
71,"Furthermore, there is evidence that a low omega-3 index, which varies with n-3 PUFA content in the diet, is predictive of sudden death (<sup><a href=""#R36"">36</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
72,"Our previous work identified a subset of patients with PAD with claudication who may benefit from n-3 PUFA supplementation (<sup><a href=""#R13"">13</a></sup>).",0,0,0,0,0,0,0,0,0,0,0
73,Screening with the omega-3 index may help identify a subgroup who may benefit from n-3 PUFA supplementation.,0,0,0,0,0,0,0,0,0,0,0
74,"More robust studies are, however, needed to address this question.",0,0,0,0,0,0,0,0,0,0,0
75,"Hence, although inclusion of the omega-3 index in our patients could provide important insight, we cannot make formal recommendations at this point.",0,0,0,0,0,0,0,0,0,0,0
76,Limitations of this study include a relatively small sample size drawn from a fairly specialized population.,0,0,0,0,0,0,0,0,0,0,0
77,"The cohort is primarily made up of Caucasian males, reflecting the patient population served by the San Francisco Veteran Affairs Medical Center; hence, this cohort may not be representative of the broader PAD population.",0,0,0,0,0,0,0,0,0,0,0
78,"Because our cohort was comprised of 98% males, our findings cannot be generalized to women with PAD.",0,0,0,0,0,0,0,0,0,0,0
79,"In addition, a history of smoking was almost universal in both groups (95% in the intervention group and 90% in the placebo group); because the two groups were essentially matched on this risk factor, we could not reliably examine its effect.",0,0,0,0,0,0,0,0,0,0,0
80,"Although it is possible that persistent smoking during the trial may have blunted the effects of omega-3 index response, we did not capture data on whether or not participants were current smokers.",0,0,0,0,0,0,0,0,0,0,0
81,Another limitation relates to compliance with omega-3 daily supplementation.,0,0,0,0,0,0,0,0,0,0,0
82,"Pill count analysis suggests that compliance was good; however, it is possible that patients did not bring back their pills for the pill count, which would lead to falsely elevated compliance rates.",0,0,0,0,0,0,0,0,0,0,0
83,"Finally, findings of this study need to be interpreted as hypothesis-generating in light of the lack of a priori power analyses.",0,0,0,0,0,0,0,0,0,0,0
84,"High-dose, short-term fish oil supplementation increased the omega-3 index and reduced <span class=""italic"">n</span>-6 PUFA content in RBCs.",0,0,0,0,0,0,0,0,0,0,0
85,Predictors of a more robust omega-3 index response included a lower BMI and a higher LDL cholesterol level.,0,0,0,0,0,0,0,0,0,0,0
86,We will continue to investigate the implications of the omega-3 index and changes in n-3 PUFA and n-6 PUFA RBC membrane content in patients with PAD in a follow-up trial (OMEGA-PAD II; NCT01979874).,0,0,0,0,0,0,0,0,0,0,0
87,"View larger version</a></span><span class=""fig-label"">Figure 1.",0,0,0,0,0,0,0,0,0,0,0
88,"<span class=""title"">Baseline omega-3 index in patients with PAD</span></span>Histogram of omega-3 index at baseline in placebo group (A) and fish oil group (B).",0,0,0,0,0,0,0,0,0,0,0
89,The histograms show a similarly right-tailed distribution in the two groups.,0,0,0,0,0,0,0,0,0,0,0
90,"View larger version</a></span><span class=""fig-label"">Figure 2.",0,0,0,0,0,0,0,0,0,0,0
91,"<span class=""title"">Change in omega-3 index</span></span>Following one month of fish oil supplementation, there was no change in the omega-3 index in the control group [4.8 ± 1.5% to 4.9 ± 1.4% (p=0.49)] (A).",0,0,0,0,0,0,0,0,0,0,0
92,The mean omega-3 index increased significantly from 5.1 ± 1.3% to 9.0 ± 1.8% (p&lt;0.0001) in the supplemented fish oil group.,0,0,0,0,0,0,0,0,0,0,0
93,"See full table</a></span><span class=""fig-label"">Table 1.",0,0,0,0,0,0,0,0,0,0,0
94,</span>Baseline Clinical Profile of the Study Population.,1,0,0,0,0,1,0,0,0,0,0
95,"See full table</a></span><span class=""fig-label"">Table 2.",0,0,0,0,0,0,0,0,0,0,0
96,</span>Changes in red blood cell PUFA composition,1,0,0,0,0,1,0,0,0,0,0
97,"See full table</a></span><span class=""fig-label"">Table 3.",0,0,0,0,0,0,0,0,0,0,0
98,</span>Factors associated with a strong response in omega-3 index in a univariate analysis,0,0,0,0,0,0,0,0,0,0,0
99,"See full table</a></span><span class=""fig-label"">Table 4.",0,0,0,0,0,0,0,0,0,0,0
100,</span>Factors Associated with a Positive Response to n-3 PUFA in a Multivariable Analysis.,0,0,0,0,0,0,0,0,0,0,0